Status and phase
Conditions
Treatments
About
The purpose of this study is to assess the safety and tolerability, describe the dose-limiting toxicities (DLTs), and determine the maximum tolerated dose (MTD) or maximum administered dose (MAD [in the absence of establishing the MTD]) for single agent MEDI3726 in subjects with mCRPC who have received prior treatment with abiraterone or enzalutamide, with or without a prior taxane-based chemotherapy in the mCRPC setting.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria:
Age ≥ 18 years at the time of screening.
Histologically confirmed diagnosis of metastatic castration-resistant prostate adenocarcinoma (mCRPC).
Documented PD in subjects with mCRPC as assessed by the Investigator and defined by at least one of the following according to the PCWG3 criteria:
Prior exposure to abiraterone or enzalutamide of at least 12 weeks in the mCRPC setting.
NOTE: Subjects who have received both abiraterone and enzalutamide in the mCRPC setting are eligible.
In dose escalation: Prior taxane-based chemotherapy in the mCRPC setting is:
Required for Arm A.
Excluded for Arm B.
Optional for Arm C.
Exclusion Criteria:
Subjects with neuroendocrine, neuroendocrine differentiation and/or small cell prostate cancer.
The subject has received any conventional or investigational anti-cancer treatment within 21 days before the first dose of investigational product, with the following modifications:
NOTE: An LHRH agonist or antagonist required for ongoing testosterone suppression will be permitted if Inclusion Criterion is satisfied.
Prior exposure to PSMA-directed therapies.
Subjects with previous radiotherapy for the treatment of unresectable, locally advanced or metastatic prostate cancer are excluded if:
Brain metastases that are untreated, symptomatic, or require therapy to control symptoms; or any radiation, surgery, or other therapy to control symptoms from brain metastases within 2 months prior to the first dose of investigational product.
Subjects with known history of peripheral vasculopathies including, but not limited to, macro and microangiopathies secondary to diabetes, peripheral arteriopathy of any cause, intermittent claudication, repeated and/or non-healing ulcers of any cause.
Primary purpose
Allocation
Interventional model
Masking
33 participants in 3 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal